Table 2 Efficacy of PA-49 against various strains of influenza virus.

From: Structure-based drug discovery for combating influenza virus by targeting the PA–PB1 interaction

Compound

CC50 a (μM)

Strain

Subtype

EC50 b (μM)

SIc

Relative titred (%)

1 μM

10 μM

Oseltamivir

>100

A/WSN/33

H1N1

4.0 ± 1.1

>24.8

14.6 ± 9.5

<1.6

PA-49

>100

A/WSN/33

H1N1

0.57 ± 0.02

>175

<0.8

<0.8

A/Puerto Rico/8/34

H1N1

0.53 ± 0.01

>189

<0.8

<0.8

A/Aichi/8/68

H3N2

0.56 ± 0.01

>179

<3.1

<3.1

A/Virginia/ATCC2/2009e

H1N1

0.62 ± 0.02

>161

N/Af

N/A

B/Lee/40

Type B

0.92 ± 0.07

>109

18.8 ± 8.8

9.4 ± 4.4

  1. aCC50; 50% cytotoxic concentration estimated by CV assay.
  2. bEC50; 50% effective concentration estimated by CV assay.
  3. cSI: selective index = CC50/EC50.
  4. dRelative virus titre in the presence of compound was estimated by HA assay vs no drug control.
  5. eClinical isolate of A(H1N1)pdm09 virus.
  6. fThis strain was not sensitive to chicken RBC.
Back to article page